USANA Health Sciences Inc. - Q1 2003 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 29, 2003. USANA Health Sciences, Inc. develops and manufactures nutritional, personal care, and weight management products distributed via a network marketing system of independent "Associates" and direct sales to "Preferred Customers." As of the period end, the company reported approximately 70,000 active Associates and 47,000 active Preferred Customers globally.
Key Financial Metrics
| Metric | Q1 2003 | Q1 2002 |
|---|---|---|
| Net Sales | $40.9 million | $28.6 million |
| Gross Profit | $31.6 million (77.4% margin) | $20.9 million (73.1% margin) |
| Net Earnings | $3.6 million | $1.1 million |
| Diluted EPS | $0.34 | $0.12 |
| Operating Cash Flow | $7.1 million | $3.2 million |
| Cash and Equivalents | $5.5 million | $3.3 million |
| Long-Term Debt | $0 | $2.6 million |
| Line of Credit | $0 outstanding | $2.9 million outstanding |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 42.8% year-over-year, driven by a 27.3% increase in the active Associate base, the launch of the Taiwan market ($2.7 million in sales), favorable foreign currency translation ($1.4 million), and price increases on key products ($1.1 million).
- Profitability: Net earnings surged 220% to $3.6 million. Gross profit margin expanded to 77.4% due to procurement efficiencies and pricing strategy changes.
- Debt Reduction: The company paid off all outstanding long-term debt and line of credit balances during the quarter, resulting in zero debt as of March 29, 2003.
- Expense Ratios: Selling, general, and administrative (SG&A) expenses decreased as a percentage of sales (23.4% vs. 28.1%) despite a $1.5 million absolute increase, primarily due to sales volume leverage.
Guidance, Outlook, and Risks
Guidance: Management expects Q2 2003 net sales of approximately $42 million and full-year 2003 sales of approximately $170 million, contingent on the success of the anticipated South Korea market opening in Q3 2003.
Outlook: Gross profit margins and associate incentive ratios are expected to approximate Q1 2003 levels for the remainder of the year. SG&A expenses are expected to rise in absolute terms but decrease as a percentage of sales.
Risks and Contingencies:
- SARS Outbreak: The Severe Acute Respiratory Syndrome outbreak in Asia poses a risk to operations and sales in affected regions due to travel restrictions and commerce disruptions.
- Geopolitical Events: The war in Iraq (commenced March 2003) presents potential future adverse effects on business operations.
- Currency Risk: Approximately 51% of sales are foreign; results are sensitive to exchange rate fluctuations. The company currently has no hedging instruments in place.
- Market Dependence: Significant reliance on the network marketing model and the ability to attract/maintain Associates.
Investor Verification Checklist
- Verify the sustainability of the 27.3% growth in the active Associate base.
- Confirm the timeline and projected revenue impact of the South Korea market launch.
- Monitor the impact of the SARS outbreak on Asian sales regions (Taiwan, Hong Kong, Japan).
- Review the company's ability to maintain gross margins as sales volume increases.
- Assess the potential dilution from future equity financing if capital needs exceed current cash flow.